A detailed history of Bank Of Montreal transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 27,433 shares of PCVX stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,433
Holding current value
$2.38 Million
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$70.52 - $117.12 $1.93 Million - $3.21 Million
27,433 New
27,433 $3.13 Million
Q2 2022

Aug 11, 2022

SELL
$17.68 - $26.58 $194,815 - $292,885
-11,019 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$17.46 - $26.36 $646 - $975
-37 Reduced 0.33%
11,019 $269,000
Q4 2021

Feb 11, 2022

BUY
$19.32 - $26.45 $2,318 - $3,174
120 Added 1.1%
11,056 $281,000
Q3 2021

Nov 12, 2021

BUY
$20.26 - $26.97 $12,095 - $16,101
597 Added 5.77%
10,936 $286,000
Q2 2021

Aug 12, 2021

BUY
$16.45 - $24.06 $170,076 - $248,756
10,339 New
10,339 $249,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.15B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.